Clinical trials: CYP19
Metastatic Breast Cancer
Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea
The objective of this study is to evaluate the real-world prescription patterns of Palbociclib in breast cancer (BC) patients who were treated with Palbociclib in combination with AI as a 1st line of therapy using the national…
- Trial name
- NCT05132101
- Testing
- Patients who received Palbociclib as first line therapy in MBC setting
- Where
- South Korea
- Volunteers
- 2,758 people
- Sponsor
- Pfizer
Postmenopausal Women With Advanced Breast Cancer
Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
To investigate the safety of letrozole monotherapy at a dose 1.0 mg/day or fadrozole monotherapy at a dose 2.0mg in Japanese postmenopausal patients with advanced breast cancer which participated in double blind study.
- Trial name
- NCT00247663
- Testing
- Letrozole
- Where
- 10 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Osteoporosis
An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice
The aim of this study is to determine the effect of aromatase inhibitors therapy on bone mineral density and compare it to the effects of tamoxifen and no hormonal therapy.
- Trial name
- NCT00767585
- Where
- Slovenia
- Volunteers
- 560 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer
Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor
A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Analytic Database to compare effectiveness (i.e., overall survival) of first line palbociclib + aromatase inhibitor…
- Trial name
- NCT05361655
- Testing
- Palbociclib + an aromatase inhibitor, Aromatase inhibitor
- Where
- United States
- Volunteers
- 2,888 people
- Sponsor
- Pfizer
Breast Cancer
Dendritic Cell Based Therapy for Breast Cancer Patients
The primary aim of this study is to investigate time to progression in breast cancer patients vaccinated with autologous dendritic cells pulsed with peptides in combination with adjuvant aromatase inhibitor (AI), Thymosin 1 alpha…
- Trial name
- NCT00935558
- Testing
- DC vaccine, aromatase inhibitor
- Where
- Denmark
- Sponsor
- Inge Marie Svane
Breast Cancer, Aromatase Inhibitors
Prevalence and Risk Factors for Pain and Related Adverse Reactions Among Breast Cancer Survivors on Aromatase Inhibitors
We obtained the occurrence of pain sensation, pain mood, sleep, etc. during endocrine therapy in breast cancer patients through telephone follow-up, and analyzed risk factors through artificial intelligence
- Conditions
- Breast Cancer, Aromatase Inhibitors, Endocrine Therapy, Pain
- Trial name
- NCT05628077
- Testing
- No intervention
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Peking University People's Hospital
Breast Cancer, Arthralgia
Androgen Therapy for Breast Cancer Patients With Aromatase Inhibitor Induced Side-Effects
The purpose of this study is to evaluate whether increasing blood levels of androgen can reduce some of the side-effects of anti-estrogen therapy (Arimidex)
- Conditions
- Breast Cancer, Arthralgia, Osteoporosis
- Trial name
- ART2 (NCT00497458)
- Testing
- Testosterone
- Where
- Australia
- Volunteers
- 90 people
- Sponsor
- Havah Therapeutics Pty Ltd
Breast Cancer
Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors
The purpose of this study to gather information about changes in the bones after stopping treatment with aromatase inhibitor/AI and denosumab.
- Trial name
- NCT05590949
- Testing
- Physical Evaluation, Dual-energy X-ray absorptiometry scans, Trabecular Bone Score
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Male Hypogonadism, Sexual Dysfunction
D-chiroinositol Administration in Hypogonadal Males
D-chiroinositol (DCI), is known as second messenger of insulin pathway, but recently several works have reported the influence of DCI on steroidogenesis.
- Trial name
- NCT04708249
- Testing
- D-chiroinositol
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Lo.Li.Pharma s.r.l
Estrogen Receptor Positive Breast Cancer, Breast Cancer
REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy
This study is investigating whether breast cancer patients who experience vaginal dryness while on anti-estrogen treatment could benefit from either vaginal estrogen or from a vaginal moisturizer called Replens.
- Trial name
- REVIVE (NCT01984138)
- Testing
- ESTRING, Replens, Vagifem
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Polly A. Niravath, MD
Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder
This study is open to women who have early-stage breast cancer and are on aromatase inhibitor (AI) therapy, and who have hypoactive sexual desire disorder (HSDD).
- Conditions
- Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder, Hormone Receptor Positive Breast Carcinoma, Breast Cancer
- Trial name
- NCT07596212
- Testing
- Aromatase Inhibitors, Bupropion, GnRH agonist
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Illinois Chicago
Breast Cancer
Adherence of Hispanic / Latina Breast Cancer - Patients to Adjuvant Aromatase Inhibitors
This is an observational trial designed to assess prospectively the adherence rate to AIs among women with invasive breast cancer (stages I-III) currently receiving AI adjuvant therapy after standard local and systemic therapy.
- Trial name
- ALPA (NCT03144037)
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
Breast Cancer, Early Breast Cancer
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who…
- Trial name
- CAMBRIA-1 (NCT05774951)
- Testing
- Camizestrant, Tamoxifen, Anastrozole
- Where
- 709 sites in United States, Argentina and 37 more
- Volunteers
- 4,300 people
- Sponsor
- AstraZeneca
Breast Cancer
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
The primary objective of Phase 1b will be to evaluate the safety and tolerability of TTI-101 when added to palbociclib and AI or fulvestrant administered orally to participants with hormone receptor-positive (HR+) human epidermal…
- Trial name
- NCT05384119
- Testing
- TTI-101, Palbociclib, Aromatase inhibitor (AI)
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Tvardi Therapeutics, Incorporated
Breast Cancer, Menopausal Symptoms
Acupuncture or Medication in Reducing Pain in Postmenopausal Women With Breast Cancer and Joint Pain
RATIONALE: Acupuncture may reduce joint pain in postmenopausal women with breast cancer. It is not yet known whether acupuncture is more effective than standard therapy analgesics in decreasing joint pain caused by aromatase…
- Conditions
- Breast Cancer, Menopausal Symptoms, Pain
- Trial name
- NCT00892268
- Testing
- acupuncture therapy, pain therapy
- Volunteers
- 68 people
- Sponsor
- University of Arizona
Metastasis Breast
Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer
The study is designed to assess the treatment outcomes following treatment with letrozole plus metronomic capecitabine in patients with hormone receptor-positive, Her2-negative advanced breast cancer who have not received prior…
- Trial name
- NCT04942899
- Testing
- letrozole
- Volunteers
- 70 people
- Sponsor
- Assiut University
Breast Cancer
Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain
Many women with breast cancer who are treated with aromatase inhibitor medications develop aches and pains during treatment, and some develop numbness and tingling in their hands and feet.
- Trial name
- NCT01028352
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Michigan Rogel Cancer Center
Hormone Dependent Neoplasms, Breast Cancer Female
HOrmone Therapy Immediately After Histological Diagnosis of Breast Cancer
Breast Cancer is a public health issue worldwide. The time from diagnosis to treatment initiation varies from country to country and regionally within a country.
- Trial name
- HOTBreast (NCT03111615)
- Testing
- Aromatase Inhibitors
- Where
- Portugal
- Volunteers
- 90 people
- Sponsor
- Centro Hospitalar Lisboa Ocidental
Musculoskeletal Symptoms, Breast Cancer
AI-based Skeleton Recognition System for Rehabilitation Exercise in Breast Cancer Survivors: A Randomized Controlled Trial
This study aims to develop and evaluate an artificial intelligence (AI)-based skeletal recognition system designed to support real-time, interactive rehabilitation exercise (RE programs.
- Conditions
- Musculoskeletal Symptoms, Breast Cancer, Endocrine Therapy, Aromatase Inhibitors
- Trial name
- AiRE-MS (NCT06642948)
- Testing
- Motor rehabilitation based on ai visual recognition
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Women With Breast Cancer
Effect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer
The goal of this interventional study is to evaluate the effect of Intravaginal Prasterone for the treatment of moderate to severe symptoms of genitourinary syndrome (GSM) due to natural, surgical or treatment-induced menopause…
- Trial name
- PROPOSE (NCT06611514)
- Testing
- Prasterone (DHEA)
- Where
- Italy
- Volunteers
- 95 people
- Sponsor
- European Institute of Oncology